DrugPatentWatch Database Preview

LIPITOR Drug Profile

« Back to Dashboard

Which patents cover Lipitor, and what generic alternatives are available?

Lipitor is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

Summary for LIPITOR

US Patents:	0
Applicants:	1
NDAs:	1
Suppliers / Packagers:	8
Bulk Api Vendors:	68
Clinical Trials:	190
Patent Applications:	4,514
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for LIPITOR
Drug Sales Revenues:	Drug sales revenues for LIPITOR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIPITOR
DailyMed Link:	LIPITOR at DailyMed

See drug prices for LIPITOR

See drug sales revenues for LIPITOR

Recent Clinical Trials for LIPITOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Central Finland Hospital District	Phase 3
Kuopio University Hospital	Phase 3
University of Aarhus	Phase 3

See all LIPITOR clinical trials

Recent Litigation for LIPITOR

Identify potential future generic entrants

District Court Litigation

Case Name	Date
Pfizer Inc. v. Sandoz Inc.	2010-02-09
Pfizer Inc. v. Mylan Pharmaceuticals Inc.	2010-02-03
MERCK SHARP & DOHME CORP. v. MYLAN PHARMACEUTICALS INC.	2009-12-16

See all LIPITOR litigation

Pharmacology for LIPITOR

Drug Class	HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors

Synonyms for LIPITOR

(|AR,|AR)-2-(4-Fluorophenyl)-|A,|A-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt

(C33H34FN2O5)2.Ca

(R,R)-2-(4-Fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt

[R-(R*, R*)]-2-(4-fluorophenyl)-(beta), (delta)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate

[R-(R*, R*)]-2-(4-fluorophenyl)-beta-, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid,calcium salt (2:1) trihydrate

1108202-55-6

110862-48-1

110862-48-1 (Parent)

134523-03-8

1370463-14-1

1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-,-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (R,R)-

1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, calcium salt (2:1), (R-(R*,R*))-

1H-Pyrrole-1-heptanoic acid, beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, calcium salt (2:1), (R-(R*,R*))-

1H-Pyrrole-1-heptanoicacid,2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-,calciumsalt(2:1),(betaR,deltaR)-

2C33H34FN2O5.Ca

334757-04-9

4CA-0208

AC1L1TZQ

ACT03226

AK106989

AKOS015896435

AM90286

AN-6412

AOB6343

AT-3134

Atorvastan

ATORVASTATIN CALCIUM

Atorvastatin calcium [USAN:USP]

Atorvastatin calcium [USAN]

Atorvastatin calcium anhydorous

Atorvastatin calcium anhydrous

Atorvastatin calcium salt

Atorvastatin Hemicalcium

Atorvastatin hemicalcium salt

BC634906

BDBM50442868

C0GEJ5QCSO

CA0146

calcium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate

calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate

calcium (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoate

Calcium (betaR,deltaR)-2-(p-fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoate (1:2)

calcium bis((3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate)

calcium bis{(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate}

calcium;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate

CAS-134523-03-8

CHEBI:50686

CHEMBL393220

CI 981

CI-981

D00887

DRG-0321

DSSTox_CID_24303

DSSTox_GSID_44303

DSSTox_RID_80143

DTXSID6044303

FQCKMBLVYCEXJB-MNSAWQCASA-L

FT-0081085

GS-3563

I06-1867

J-006551

KB-270796

Kolevas

KS-00000IS3

Lipibec

Lipitor (TN)

Liprimar

LS-136974

MFCD00899261

MolPort-003-986-383

NCGC00159458-03

NCGC00159458-05

NCGC00255845-01

PD 134298-38A

Prevencor

Ranbaxy's Storvas

Rotacor

SC-76963

SCHEMBL3832

Sortis

Storvas

SW219144-1

SYN3020

Tahor

TL8000809

Torvast

Tox21_111685

Tox21_111685_1

Tox21_302373

Tulip

UNII-C0GEJ5QCSO

VA10343

YM 548

YM-548

Paragraph IV (Patent) Challenges for LIPITOR

Tradename	Dosage	Ingredient	NDA	Submissiondate
LIPITOR	TABLET;ORAL	atorvastatin calcium	020702

US Patents and Regulatory Information for LIPITOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-001	Dec 17, 1996	AB	RX	Yes	No
Pfizer	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-004	Apr 7, 2000	AB	RX	Yes	Yes
Pfizer	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-002	Dec 17, 1996	AB	RX	Yes	No

Expired US Patents for LIPITOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-003	Dec 17, 1996
Pfizer	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-003	Dec 17, 1996
Pfizer	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-001	Dec 17, 1996